Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more
Oncopeptides AB (ONCO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -23.926x
Based on the latest financial reports, Oncopeptides AB (ONCO) has a cash flow conversion efficiency ratio of -23.926x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-156.43 Million) by net assets (Skr6.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncopeptides AB - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Oncopeptides AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oncopeptides AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncopeptides AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schloss Wachenheim AG
F:SWA
|
0.020x |
|
CHOROKBAEM COMPANY Co. Ltd
KQ:052300
|
0.032x |
|
SDI Ltd
AU:SDI
|
0.112x |
|
Gogoro Inc
NASDAQ:GGR
|
0.079x |
|
Cuprum
SN:CUPRUM
|
0.041x |
|
Shihlin Development Company Limited
TWO:5324
|
-0.058x |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
0.156x |
|
PharmGen Science Inc
KO:004720
|
0.008x |
Annual Cash Flow Conversion Efficiency for Oncopeptides AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of Oncopeptides AB from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr54.28 Million | Skr-260.57 Million | -4.800x | +2.49% |
| 2023-12-31 | Skr56.78 Million | Skr-279.49 Million | -4.922x | -244.49% |
| 2022-12-31 | Skr294.29 Million | Skr-420.51 Million | -1.429x | +80.13% |
| 2021-12-31 | Skr210.87 Million | Skr-1.52 Billion | -7.191x | -219.98% |
| 2020-12-31 | Skr576.90 Million | Skr-1.30 Billion | -2.247x | -159.38% |
| 2019-12-31 | Skr797.01 Million | Skr-690.57 Million | -0.866x | +18.00% |
| 2018-12-31 | Skr315.83 Million | Skr-333.73 Million | -1.057x | -62.69% |
| 2017-12-31 | Skr418.00 Million | Skr-271.50 Million | -0.650x | +83.59% |
| 2016-12-31 | Skr26.34 Million | Skr-104.26 Million | -3.959x | -119.49% |
| 2015-12-31 | Skr-2.60 Million | Skr-52.81 Million | 20.311x | +591.36% |
| 2014-12-31 | Skr7.61 Million | Skr-31.44 Million | -4.134x | -- |